These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 2959047)

  • 21. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis "in vivo".
    Landolfi R; De Candia E; Rocca B; Ciabattoni G; Antinori A; Masetti R; Patrono C
    Thromb Haemost; 1994 Dec; 72(6):942-6. PubMed ID: 7740468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
    Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
    Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of platelet and vascular eicosanoids in the pathophysiology of ischemic heart disease.
    Chierchia S; Patrono C
    Fed Proc; 1987 Jan; 46(1):81-8. PubMed ID: 3542579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effect of ibuprofen on endothelial and platelet prostaglandin synthesis.
    Parks WM; Hoak JC; Czervionke RL
    J Pharmacol Exp Ther; 1981 Nov; 219(2):415-9. PubMed ID: 7026767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin.
    Evangelista V; Manarini S; Di Santo A; Capone ML; Ricciotti E; Di Francesco L; Tacconelli S; Sacchetti A; D'Angelo S; Scilimati A; Sciulli MG; Patrignani P
    Circ Res; 2006 Mar; 98(5):593-5. PubMed ID: 16484611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thromboxane synthetase inhibitors, thromboxane receptor antagonists, and aspirin in cardiovascular disease.
    Dorn GW; Halushka PV
    Ration Drug Ther; 1985 Jul; 19(7):1-7. PubMed ID: 2997839
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of thromboxane receptor antagonists in cardiovascular disease.
    Smith EF
    Prog Clin Biol Res; 1989; 301():29-38. PubMed ID: 2529549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roles of prostanoids in the pathogenesis of cardiovascular diseases.
    Yuhki K; Kashiwagi H; Kojima F; Kawabe J; Ushikubi F
    Int Angiol; 2010 Apr; 29(2 Suppl):19-27. PubMed ID: 20357745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
    J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unstable angina.
    Mikhailidis DP; Jagroop IA
    Am Heart J; 1996 Jun; 131(6):1234-5. PubMed ID: 8644613
    [No Abstract]   [Full Text] [Related]  

  • 31. Eicosanoid biosynthesis in human cardiovascular disease.
    Fitzgerald GA; Catella F; Oates JA
    Hum Pathol; 1987 Mar; 18(3):248-52. PubMed ID: 3546074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of [3H]-GR 32191 binding to the thromboxane (TP) receptor of human platelets.
    Armstrong RA; Lumley P; Humphrey PP
    Br J Pharmacol; 1989 Dec; 98 Suppl():843P. PubMed ID: 2532945
    [No Abstract]   [Full Text] [Related]  

  • 33. [Thromboxane A2 (TXA2), thromboxane B2 (TXB2)].
    Ueda T; Hashimoto T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():24-7. PubMed ID: 16149442
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostaglandin receptors in the cardiovascular system: potential selectivity from receptor subtypes or modified responsiveness.
    Keen M; Kelly E; MacDermot J
    Eicosanoids; 1989; 2(4):193-7. PubMed ID: 2698224
    [No Abstract]   [Full Text] [Related]  

  • 35. Mechanisms of eicosanoid action.
    FitzGerald GA; Murray R; Moran N; Funk C; Charman W; Clarke R; Furci L; Fitzgerald DJ
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():577-81. PubMed ID: 1825381
    [No Abstract]   [Full Text] [Related]  

  • 36. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?
    Halushka MK; Halushka PV
    Circulation; 2002 Apr; 105(14):1620-2. PubMed ID: 11940535
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic opportunities in vasoocclusive disease.
    Ritter JM; Dollery CT
    Circulation; 1986 Feb; 73(2):240-3. PubMed ID: 2935325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The inhibition of thromboxane A2 release by beta-sympathomimetics.
    Ekblad U
    Gynecol Obstet Invest; 1990; 30(3):192. PubMed ID: 1979955
    [No Abstract]   [Full Text] [Related]  

  • 39. Thromboxanes as mediators of cardiovascular disease states.
    Lefer AM; Smith JB
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():473-5. PubMed ID: 2936146
    [No Abstract]   [Full Text] [Related]  

  • 40. "Female evanescence".
    Hornig LS; Tolpin M; Speizer JJ
    Science; 1979 Jul; 205(4403):260. PubMed ID: 17747028
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.